Regenxbio Inc [RGNX] stock is trading at $11.19, up 18.66%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RGNX shares have gain 30.27% over the last week, with a monthly amount glided 21.10%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Goldman started tracking the stock with Buy rating on June 07, 2024, and set its price target to $38. On March 11, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $36 on the stock. RBC Capital Mkts upgraded its rating to a Outperform and increased its price target to $35 on March 08, 2024. Leerink Partners upgraded its rating to a Outperform but $37 remained the price target by the analyst firm on March 06, 2024. In a note dated November 01, 2023, Stifel initiated an Buy rating and provided a target price of $35 on this stock.
Regenxbio Inc [RGNX] stock has fluctuated between $8.53 and $28.80 over the past year. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. Regenxbio Inc [NASDAQ: RGNX] shares were valued at $11.19 at the most recent close of the market. An investor can expect a potential return of 203.84% based on the average RGNX price forecast.
Analyzing the RGNX fundamentals
Regenxbio Inc [NASDAQ:RGNX] reported sales of 84.33M for the trailing twelve months, which represents a drop of -16.31%. Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at -2.89%, Pretax Profit Margin comes in at -2.83%, and Net Profit Margin reading is -2.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.71 and Total Capital is -0.59. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.25 points at the first support level, and at 9.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.87, and for the 2nd resistance point, it is at 12.56.
Ratios To Look Out For
For context, Regenxbio Inc’s Current Ratio is 3.05. In addition, the Quick Ratio stands at 3.05 and the Cash Ratio stands at 0.55. Considering the valuation of this stock, the price to sales ratio is 6.56, the price to book ratio is 1.84.
Transactions by insiders
Recent insider trading involved KARABELAS ARGERIS N, Director, that happened on Oct 01 ’24 when 10000.0 shares were sold. Director, KARABELAS ARGERIS N completed a deal on Sep 03 ’24 to sell 10000.0 shares. Meanwhile, Director KARABELAS ARGERIS N sold 10100.0 shares on Aug 01 ’24.
